Could DEA Be Next? EPA Firings Spark Questions About DEA's Accountability in MMJ's Marijuana Licensing Delays
Press Release

Could DEA Be Next? EPA Firings Spark Questions About DEA's Accountability in MMJ's Marijuana Licensing Delays

After the EPA dismissed employees who publicly criticized its leadership, attention is turning to the Drug Enforcement Administration's Diversion Control Division, long accused of obstructing FDA-approved cannabis research. With DEA officials Matthew Strait and Thomas Prevoznik retired and attorney Aarathi Haig facing ethical questions, patient advocates warn that new DEA Administrator Terry Cole may soon be forced to take similar disciplinary action against insiders who blocked MMJ BioPharma Cultivation's clinical trials for Huntington's disease and Multiple Sclerosis.

Read More